Brief: Abbisko Cayman Says CSF-1R Inhibitor Pimicotinib Granted Priority Medicine Designation
07/06/2023 15:46
June 7 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* CSF-1R INHIBITOR PIMICOTINIB GRANTED PRIORITY MEDICINE
DESIGNATION BY EUROPEAN MEDICINES AGENCY
Source text for Eikon: ID:
Further company coverage: 2256.HK
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration